By Josh White
Date: Friday 21 Mar 2025
(Sharecast News) - Angle announced on Friday the successful completion of assay development projects for AstraZeneca and Eisai, further expanding its portfolio of liquid biopsy solutions and strengthening its position as a partner to the pharmaceutical industry in oncology drug development.
Angle's Parsortix system used in 'breakthrough' ... | 24-Jan-2025 | ShareCast |
Berenberg slashes target price on Angle | 23-Jan-2025 | ShareCast |
Angle signs new agreement US biotech Recursion | 19-Sep-2024 | ShareCast |
Angle unveils plans to raise more than £10m | 05-Jun-2024 | ShareCast |
Angle reports promising results from Parsortix s... | 16-May-2024 | ShareCast |
Issue of LTIP Options and Share Options | 21-Mar-2025 | 07:00 | RNS |
Results of Eisai Phase 2 pilot study | 21-Mar-2025 | 07:00 | RNS |
Analysis of CTC-DNA and ctDNA using Illumina assay | 29-Jan-2025 | 07:00 | RNS |
Trading Update | 23-Jan-2025 | 07:00 | RNS |
Half-year Report | 26-Sep-2024 | 07:00 | RNS |
Market report: Monday latest | 07-Apr-2008 | Daily Mail |
T&T float sinks amid turmoil | 07-Feb-2008 | Times |
Carphone buzz may just be empty static | 01-Feb-2008 | Guardian |
Greene King looks to life after cigarette ban | 02-Jul-2007 | The Independent |
The Week Ahead: BSkyB boosted by 200,000 new sub... | 29-Jan-2007 | The Independent |
No recent information was found.
Currency | UK Pounds |
Share Price | 8.25p |
Change Today | -0.15p |
% Change | -1.79 % |
52 Week High | 23.21 |
52 Week Low | 7.25 |
Volume | 483,704 |
Shares Issued | 322.64m |
Market Cap | £26.62m |
RiskGrade | 312 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
17:06 | 21,324 @ 8.25p |
16:17 | 4,610 @ 8.00p |
16:08 | 5,985 @ 8.37p |
15:29 | 10,149 @ 8.37p |
14:58 | 86,148 @ 8.13p |
CEO | Andrew D Newland |
Finance Director | Ian F Griffiths |
Chair | Jan Groen |
You are here: research